Publications by authors named "A Eleftheraki"

Article Synopsis
  • The study aimed to assess the safety and pharmacokinetics of a new drug, BI 1291583, which inhibits cathepsin C to potentially reduce inflammation in bronchiectasis patients.
  • Conducted as a randomized, double-blind, placebo-controlled trial, it involved healthy Japanese males and evaluated both single and multiple doses for any related adverse events and drug absorption levels.
  • Results indicated that the drug was safe and well-tolerated, with no serious side effects and an adequate benefit-risk ratio, suggesting it can be used in future clinical trials involving bronchiectasis patients without needing dose adjustments.
View Article and Find Full Text PDF

Lower-extremity external rotation, commonly known as turnout, is a fundamental skill in dance. Limited data exist regarding joint range of motion and strength in pre-professional young dancers and non-dancers. This study aimed to evaluate the differences in hip range of motion and hip strength between pre-professional ballet dancers and non-dancers.

View Article and Find Full Text PDF
Article Synopsis
  • Bronchiectasis is caused by high levels of neutrophil serine protease (NSP) activity, and inhibiting Cathepsin C (CatC) may help decrease lung damage caused by neutrophils.
  • A Phase II trial tested a new CatC inhibitor (BI 1291583) in 322 adults with bronchiectasis, comparing different doses (1, 2.5, 5 mg) to a placebo over 24 to 48 weeks.
  • Results showed that higher doses of BI 1291583 significantly delayed the onset of pulmonary exacerbations, with the 2.5 mg dose being the most effective, while the safety profile was comparable to that of the placebo. *
View Article and Find Full Text PDF

Novel treatments are needed to reduce inflammation, improve symptoms, address exacerbations, and slow disease progression in bronchiectasis. Cathepsin C (CatC) inhibition promises to achieve this through reduction of neutrophil-derived serine protease (including neutrophil elastase [NE] and proteinase 3 [PR3]) activation. Here, we present the phase I characterization of the novel CatC inhibitor, BI 1291583.

View Article and Find Full Text PDF

Rationale And Objective: Cystic fibrosis (CF) is caused by mutations in the CF Transmembrane Conductance Regulator (CFTR) gene. CFTR modulators offer significant improvements, but approximately 10% of patients remain nonresponsive or are intolerant. This study provides an analysis of rSIV.

View Article and Find Full Text PDF